|
gptkbp:instanceOf
|
antiretroviral therapy
protease inhibitor
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AE02
|
|
gptkbp:brand
|
gptkb:Crixivan
|
|
gptkbp:CASNumber
|
150378-17-9
|
|
gptkbp:category
|
antiviral drug
HIV/AIDS drug
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to indinavir
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
1.8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C36H47N5O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Indinavir
|
|
gptkbp:interactsWith
|
gptkb:rifampin
gptkb:ritonavir
gptkb:ketoconazole
saquinavir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2006
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
60%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
lipodystrophy
kidney stones
hyperbilirubinemia
|
|
gptkbp:synonym
|
gptkb:MK-639
gptkb:IDV
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
6
|